Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of rmhTNF plus docetaxel-platinum chemotherapy in advanced non-small-cell lung cancer
ChiCTR-IPR-14005500Phase 3Completed
- Sponsor
- West China Medical Center
- Start
- Nov 2002
- Countries
- 1
01
Overview
Phase 3, randomised trial of recombinant mutated human tumor necrosis factor in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West China Medical Center. Primary endpoints: response and survival. Started Nov 2002; status: completed.
02
Drugs
recombinant mutated human tumor necrosis factor
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005500.